RABEP2

Across TCGA pan-cancer cohorts, RABEP2 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RABEP2 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RABEP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RABEP2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, BRCA, and KIRC are the cancer types where RABEP2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.162	0.685	.018	18	view →
BRCA	OS	Median	All	0.115	0.578	.024	12	view →
KIRC	DFS	Median	IV	0.205	0.603	.001	6	view →
UCEC	DFS	Median	All	0.973	0.829	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RABEP2–HNSC (OS)

Open the HNSC breakdown →